,feature,Maximum hospitalization rate | corr,Maximum hospitalization rate | p-value,If hospitalization threshold passed | corr,If hospitalization threshold passed | p-value
0,Obs: Incidence rate,0.3736506474112292,5.17586576999831e-18,0.22039105123141794,6.454872069684391e-07
1,Obs: Incidence rate-ave-2wk,0.37265391333924974,6.435254655936263e-18,0.21116389087989335,1.9000801429990754e-06
2,Obs: Incidence rate-slope-4wk,0.35750506499014245,1.607930958699764e-16,0.1589188661202144,0.0003606299877387763
3,Obs: New hospitalization rate,0.4692326596332306,9.669228288721022e-29,0.14983305382641843,0.0007766785856447897
4,Obs: New hospitalization rate-ave-2wk,0.4591488546962461,1.9280644257519795e-27,0.1491147065853225,0.0008237803303313019
5,Obs: New hospitalization rate-slope-4wk,0.44386927771620777,1.4923384965998641e-25,0.11390515355385547,0.010805634011270328
6,Obs: % of incidence due to Novel,0.1874746857566576,2.4535112390693135e-05,0.2482670879209151,1.8460471121320177e-08
7,Obs: % of incidence due to Novel-ave-2wk,0.177320279704932,6.699477664106888e-05,0.24156806418609922,4.5178358106435974e-08
8,Obs: % of incidence due to Novel-slope-4wk,0.23000213057958666,1.992810573832223e-07,0.20920877406146524,2.3740613341609553e-06
9,Obs: % of incidence due to Vaccinated,0.10558952524754348,0.01818892107158756,0.23070676328037554,1.8245296158683643e-07
10,Obs: % of incidence due to Vaccinated-ave-2wk,0.09246485782185755,0.03875001445628113,0.2173003013284343,9.3161823272238e-07
11,Obs: % of incidence due to Vaccinated-slope-4wk,0.21849771154459086,8.086822542303044e-07,0.26423130980505083,1.966195943062912e-09
12,Obs: % of new hospitalizations due to Novel,0.1636957034531255,0.00023690923608613444,0.24139333314495928,4.6229240821508364e-08
13,Obs: % of new hospitalizations due to Novel-ave-2wk,0.1615354913061225,0.0002869009738170132,0.2289913105165383,2.2605606122704795e-07
14,Obs: % of new hospitalizations due to Novel-slope-4wk,0.11971341631880167,0.007366245270063756,0.08248500459983756,0.06533690597856899
15,Obs: % of new hospitalizations due to Vaccinated,0.06794359030422832,0.12921216390467344,0.1406370564530341,0.0016185043793656554
16,Obs: % of new hospitalizations due to Vaccinated-ave-2wk,0.0682345155554982,0.12757676126909173,0.14291776225372257,0.0013543698087640792
17,Obs: % of new hospitalizations due to Vaccinated-slope-4wk,0.04065504665970562,0.36431464788826035,0.05863012087799409,0.19058375351447165
18,Obs: Prevalence susceptible,0.17983541325220148,5.250322759399579e-05,0.1366343831096351,0.0021989084422145417
19,Obs: Cumulative vaccination rate,-0.21405560471521368,1.3615623676848382e-06,-0.24075127668989307,5.029744003077714e-08
20,Obs: Cumulative hospitalization rate,0.3370185136464018,9.571647334462072e-15,0.13503662131020686,0.0024795702284577184
21,R0,-0.014370136127870772,0.748560283907527,-0.06306044876452799,0.15914681424630453
22,Duration of infectiousness-dominant,0.01970675728556497,0.6602295424925166,0.01982682629760782,0.6582901033323466
23,Prob Hosp for 18-29,-0.009400623760430517,0.8339152081342432,0.037421642207499224,0.40373375430818464
24,Relative prob hosp by age-0,-0.010349584912768835,0.8174307833865166,0.01988087951965096,0.6574177443687288
25,Relative prob hosp by age-1,0.01870496922937925,0.6764988560615403,-0.004289088475808732,0.9237847884559739
26,Relative prob hosp by age-2,-0.006803676910578594,0.8793795275524302,0.006971436659609847,0.8764288975433239
27,Relative prob hosp by age-4,-0.12769122843375125,0.004238660226967707,-0.07787188931182479,0.0819376278018221
28,Relative prob hosp by age-5,-0.10092529720650167,0.02401588206813547,-0.022090068818996268,0.6221731367389566
29,Relative prob hosp by age-6,0.028976619043106652,0.5179873572754735,0.01287003092226177,0.7740554723729564
30,Relative prob hosp by age-7,0.011372849206804187,0.7997456069262123,-0.11012828494622108,0.013744275365268297
31,Ratio of hospitalization probability by profile-1,-0.06699979984173796,0.13462946982865462,-0.030657785136882172,0.49399164294593145
32,Ratio of hospitalization probability by profile-2,-0.044132675597064845,0.3246994317368371,-0.0766237596748497,0.0869726166918693
33,Ratio transmissibility by profile-1,-0.0071850425164603805,0.8726743885019298,0.0647761608674464,0.14808381829404604
34,Ratio transmissibility by profile-2,-0.015697973630098026,0.7262183358233042,0.0038654896157891863,0.9312923580187686
35,Ratio of infectiousness duration by profile-1,-0.017069039459787504,0.7033904130609205,0.019291777861801314,0.6669500562152573
36,Ratio of infectiousness duration by profile-2,-0.008231092654828341,0.8543309701132061,0.057299267846748166,0.2008636646533879
37,Duration of R-0,-0.017254506080247103,0.7003222703542938,0.019291627018663063,0.6669525039832633
38,Duration of R-1,-0.011771086633282747,0.7928898775968227,-0.04306521081231304,0.33655061735210784
39,Duration of R-2,-0.05763320161261058,0.19824712432855515,-0.0424460414477719,0.34355026493010454
40,Duration of vaccine immunity,-0.07205284842737547,0.10757037081617353,-0.08714309741097216,0.051485864645460545
41,Prob novel strain params-0,-0.06211470236925371,0.16550580005070398,-0.09828111085860347,0.027988013051319774
42,Prob novel strain params-1,0.0013860808758446538,0.9753364087340192,-0.02494615171381709,0.5778667841351238
43,Prob novel strain params-2,-3.3413218232729956e-05,0.9994053588207957,0.002666108198941679,0.9525802402095931
44,Vaccine effectiveness against infection with novel,-0.009290541081838537,0.8358323234618746,-0.02508589564256404,0.5757374369469264
45,PD Y1 thresholds-0,-0.060954739331643575,0.173563108083992,-0.00447681951639054,0.9204596983130394
46,PD Y1 thresholds-1,0.01525223385142373,0.7336934937031719,-0.046249307668037934,0.3020112532764074
47,Change in contacts - PD Y1,0.08557487436154353,0.055846442064744796,0.09505572819195696,0.03358623870528562
48,Change in contacts - PD Y1+,0.024242642329096925,0.5886422161634729,0.018616733456772932,0.6779392091780629
